[1] Parisi R, Symmons DP, Griffiths CE, et al.Global epidemiology of psoriasis: a systematic review of incidence and prevalence[J]. J Invest Dermatol,2013,133(2):377-385.
[2] Ogdie A, Weiss P.The Epidemiology of Psoriatic Arthritis[J]. Rheum Dis Clin North Am,2015,41(4):545-568.
[3] Moll JM, Wright V.Psoriatic arthritis[J]. Semin Arthritis Rheum,1973,3(1):55-78.
[4] Gladman DD, Shuckett R, Russell ML, et al.Psoriatic arthritis (PSA)--an analysis of 220 patients[J]. Q J Med,1987,62(238):127-141.
[5] Caso F, Del Puente A, Oliviero F, et al.Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study[J]. Clin Rheumatol,2018,37(3):579-586.
[6] Polachek A, Touma Z, Anderson M, et al.Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies[J]. Arthritis Care Res (Hoboken),2017,69(1):67-74.
[7] Wong K, Gladman DD, Husted J, et al.Mortality studies in psoriatic arthritis: results from a single outpatient cli-nic. I. Causes and risk of death[J]. Arthritis Rheum,1997, 40(10):1868-1872.
[8] Reich K, Krüger K, Mössner R, et al.Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis[J]. Br J Dermatol,2009,160(5):1040-1047.
[9] Spelman L, Su JC, Fernandez-Peñas P, et al.Frequency of undiagnosed psoriatic arthritis among psoriasis patients in Australian dermatology practice[J]. J Eur Acad Dermatol Venereol,2015,29(11):2184-2191.
[10] Mease PJ, Gladman DD, Papp KA, et al.Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics[J]. J Am Acad Dermatol,2013,69(5):729-735.
[11] Villani AP, Rouzaud M, Sevrain M, et al.Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis[J]. J Am Acad Dermatol,2015,73(2):242-248.
[12] Sørensen J, Hetland ML, all departments of rheumatology in Denmark. Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry[J]. Ann Rheum Dis,2015,74(3):e12.
[13] Payet J, Goulvestre C, Bialé L, et al.Anticyclic citrullinated peptide antibodies in rheumatoid and nonrheumatoid rheumatic disorders: experience with 1 162 patients[J]. J Rheumatol,2014,41(12):2395-2402.
[14] Taylor W, Gladman D, Helliwell P, et al.Classification criteria for psoriatic arthritis: development of new criteria from a large international study[J]. Arthritis Rheum,2006, 54(8):2665-2673.
[15] Poggenborg RP, Østergaard M, Terslev L.Imaging in Psoriatic Arthritis[J]. Rheum Dis Clin North Am,2015, 41(4):593-613.
[16] Palazzi C, Lubrano E, D'Angelo S, et al. Beyond early diagnosis: occult psoriatic arthritis[J]. J Rheumatol,2010, 37(8):1556-1558.
[17] Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis[J]. Ann Rheum Dis,2015,74(6):1045-1050.
[18] Roubille C, Richer V, Starnino T, et al.The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis[J]. Ann Rheum Dis,2015,74(3):480-489.
[19] Coates LC, Kavanaugh A, Mease PJ, et al.Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis[J]. Arthritis Rheumatol,2016,68(5):1060-1071.
[20] Gossec L, Smolen JS, Ramiro S, et al.European League Against Rheumatism(EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update[J]. Ann Rheum Dis,2016,75(3):499-510.
[21] 戴生明. 银屑病关节炎的治疗[M]// 戴生明. 银屑病关节炎. 北京: 人民卫生出版社,2018:257-287.
[22] Kingsley GH, Kowalczyk A, Taylor H, et al.A randomi-zed placebo-controlled trial of methotrexate in psoriatic arthritis[J]. Rheumatology (Oxford),2012,51(8):1368-1377.
[23] Smolen JS, Schöls M, Braun J, et al.Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force[J]. Ann Rheum Dis,2018,77(1):3-17.
[24] Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial[J]. Lancet,2015,386(10012):2489-2498.
[25] Coates LC, Fransen J, Helliwell PS.Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment[J]. Ann Rheum Dis,2010,69(1):48-53.
[26] Schoels MM, Aletaha D, Alasti F, et al.Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score[J]. Ann Rheum Dis,2016,75(5):811-818.
[27] Mease PJ, Genovese MC, Greenwald MW, et al.Brodalumab, an anti-IL17RA monoclonal antibody, in psoria-tic arthritis[J]. N Engl J Med,2014,370(24):2295-2306.
[28] Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixeki-zumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase Ⅲ trial SPIRIT-P1[J]. Ann Rheum Dis,2017,76(1):79-87.
[29] Kavanaugh A, Ritchlin C, Rahman P, et al.Ustekinu-mab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials[J]. Ann Rheum Dis,2014,73(6):1000-1006.
[30] Mease PJ, Gottlieb AB, van der Heijde D, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase Ⅲ study in psoriatic arthritis[J]. Ann Rheum Dis,2017,76(9):1550-1558.
[31] Edwards CJ, Blanco FJ, Crowley J, et al.Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoria-tic arthritis and current skin involvement: a phase Ⅲ, randomised, controlled trial(PALACE 3)[J]. Ann Rheum Dis,2016,75(6):1065-1073.
[32] Mease P, Hall S, FitzGerald O, et al. Tofacitinib or Adali-mumab versus Placebo for Psoriatic Arthritis[J]. N Engl J Med,2017,377(16):1537-1550.
